Cellectis (CLLS) Capital Expenditures (2015 - 2026)

Cellectis' Capital Expenditures history runs 12 years deep, the most recent figure standing at -$265000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures rose 32.91% year-over-year to -$265000.0; the TTM figure through Mar 2026 stood at $130000.0 (down 94.6% YoY), while the FY2024 annual figure was $2.6 million, changed N/A from the prior year.
• Capital Expenditures was -$265000.0 for Q1 2026 at Cellectis, down from $1.9 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $4.6 million in Q4 2024 to a low of -$1.2 million in Q3 2025.
• Historically, Capital Expenditures has averaged $279352.9 across 5 years, with a median of -$305000.0 in 2025.
• Biggest YoY gain for Capital Expenditures was 479.17% in 2024; the steepest drop was 284.44% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $4.4 million in 2022, then slumped by 81.97% to $797000.0 in 2023, then jumped by 479.17% to $4.6 million in 2024, then sank by 59.25% to $1.9 million in 2025, then sank by 114.09% to -$265000.0 in 2026.
• The last three Capital Expenditures figures came in at -$265000.0 (Q1 2026), $1.9 million (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.